中文 |
English |
Email Alert
多肽介导的肿瘤靶向纳米递药系统
Peptide-Mediated Nano Drug Delivery System for Tumor Targeting
肿瘤靶向纳米递药系统是指利用肿瘤组织特殊的生理病理特点, 由纳米载体包载肿瘤诊疗药物构建而成的对肿瘤组织具有靶向定位功能的药物递送系统。多肽介导的肿瘤靶向纳米递药系统是肿瘤靶向递药领域较新的一个研究方向, 本文综述了该研究方向的四个重要发展历程--单功能靶向、双功能靶向、肿瘤穿透和环境响应型靶向纳米递药系统, 并介绍了各类递药系统的设计原理和典型研究案例。此外, 对目前多肽介导的纳米递药系统存在的优势与不足进行了分析。最后, 针对当前主动靶向肿瘤递药系统存在的研究困境, 提出了一种新型肿瘤靶向递药策略--“系统性靶向”策略。随着相关学科和多学科交叉的发展, 多肽介导的肿瘤靶向纳米递药系统将在肿瘤治疗中扮演更为重要的角色。
Nano drug delivery system for tumor targeting is composed of drugs for tumor diagnosis or treatment and nanocarriers with targetability to tumor tissues by taking advantage of the physiological and pathological characteristics of tumor. Peptide-mediated nano drug delivery system is a relatively new research direction in the tumor targeted delivery field. In this review, we introduce four important development courses in the research direction: single functional targeted, dual functional targeted, tumor-penetrating and environment-sensitive targeted nano drug delivery system, and the corresponding design principles and typical examples. In addition, the advantages and disadvantages of the peptide-mediated nano drug delivery system are discussed. Finally, in view of the current dilemma of active targeting drug delivery systems, we propose a novel tumor-targeted drug delivery strategy: the “systematic targeting” strategy. Temporally, the systematic targeting drug delivery system can stably penetrate through a series of barriers, and efficiently release the drug at the target site. Spatially, it not only kill the tumor cells, but also destroy the tumor microenvironment which is essential to the tumor growth. Ultimately, it can realize the systematic targeting therapy for tumors. With the development of related disciplines and multi-disciplinary subjects, peptide-mediated nano drug delivery system for tumor targeting will play a more important role in cancer therapy. Contents
1 Introduction
2 The physiological basis for tumor targeting
3 Peptide-mediated nano drug delivery system for tumor targeting
3.1 Single functional targeted nano drug delivery system
3.2 Dual functional targeted nano drug delivery system
3.3 Tumor penetrating nano drug delivery system
3.4 Environment-sensitive targeted nano drug delivery system
4 Strengths and weaknesses of peptide-mediated delivery system for tumor targeting
5 Summary and outlook
peptide-mediated
[1] Zhou Y, Kopecek J. J. Drug. Target., 2013, 21: 1-26
[2] Folkman J. N. Engl. J. Med., 1971, 285: 1182-1186
[3] Rezaei S J, Nabid M R, Niknejad H, Entezami A A. Int. J. Pharm., 2012, 437: 70-79
[4] Liu D, Liu F, Liu Z, Wang L, Zhang N. Mol. Pharm., 2011, 8: 2291-2301
[5] McQuade P, Knight L C, Welch M J. Bioconjug. Chem., 2004, 15: 988-996
[6] Jubeli E, Moine L, Nicolas V, Barratt G. Int. J. Pharm., 2012, 426: 291-301
[7] Fogal V, Zhang L, Krajewski S, Ruoslahti E. Cancer Res., 2008, 68: 7210-7218
[8] Markovsky E, Baabur-Cohen H, Eldar-Boock A, Omer L, Tiram G, Ferber S, Ofek P, Polyak D, Scomparin A, Satchi-Fainaro R. J. Control Release, 2012, 161: 446-460
[9] Danhier F, Feron O, Preat V. J. Control Release., 2010, 148: 135-146
[10] Gao H, Shi W, Freund L B. Proc. Natl. Acad. Sci. U. S. A., 2005, 102: 9469-9474
[11] Santoro L, Boutaleb S, Garambois V, Bascoul-Mollevi C, Boudousq V, Kotzki P O, Pelegrin M, Navarro-Teulon I, Pelegrin A, Pouget J P. J. Nucl. Med., 2009, 50: 2033-2041
[12] Dagar S, Krishnadas A, Rubinstein I, Blend M J, Onyuksel H. J. Control Release, 2003, 91: 123-133
[13] Zhan C, Gu B, Xie C, Li J, Liu Y, Lu W. J. Control Release, 2010, 143: 136-142
[14] Zhang Y, Yang M, Park J H, Singelyn J, Ma H, Sailor M J, Ruoslahti E, Ozkan M, Ozkan C. Small, 2009, 5: 1990-1996
[15] Maeda N, Takeuchi Y, Takada M, Sadzuka Y, Namba Y, Oku N. J. Control Release, 2004, 100: 41-52
[16] Lu Z X, Liu L T, Qi X R. Int. J. Nanomed., 2011, 6: 1661-1673
[17] Holig P, Bach M, Volkel T, Nahde T, Hoffmann S, Muller R, Kontermann R E. Protein Eng. Des. Sel., 2004, 17: 433-441
[18] Pastorino F, Brignole C, Marimpietri D, Cilli M, Gambini C, Ribatti D, Longhi R, Allen T M, Corti A, Ponzoni M. Cancer Res., 2003, 63: 7400-7409
[19] Kondo M, Asai T, Katanasaka Y, Sadzuka Y, Tsukada H, Ogino K, Taki T, Baba K, Oku N. Int. J. Cancer., 2004, 108: 301-306
[20] Yan Z, Wang F, Wen Z, Zhan C, Feng L, Liu Y, Wei X, Xie C, Lu W. J. Control Release, 2012, 157: 118-125
[21] Yan Z, Zhan C, Wen Z, Feng L, Wang F, Liu Y, Yang X, Dong Q, Liu M, Lu W. Nanotechnology, 2011, 22: art. no. 415103
[22] Xin H, Jiang X, Gu J, Sha X, Chen L, Law K, Chen Y, Wang X, Jiang Y, Fang X. Biomaterials, 2011, 32: 4293-4305
[23] Mei D, Gao H, Gong W, Pang Z, Jiang X, Chen J. African Journal of Pharmacy and Pharmacology, 2011, 5: 409-414
[24] Derfus A M, Chen A A, Min D H, Ruoslahti E, Bhatia S N. Bioconjug. Chem., 2007, 18: 1391-1396
[25] Hu Q, Gu G, Liu Z, Jiang M, Kang T, Miao D, Tu Y, Pang Z, Song Q, Yao L, Xia H, Chen H, Jiang X, Gao X, Chen J. Biomaterials, 2013, 34: 1135-1145
[26] Sugahara K N, Teesalu T, Karmali P P, Kotamraju V R, Agemy L, Girard O M, Hanahan D, Mattrey R F, Ruoslahti E. Cancer Cell, 2009, 16: 510-520
[27] Garg A, Kokkoli E. Curr. Pharm. Biotechnol., 2011, 12: 1135-1143
[28] Negussie A H, Miller J L, Reddy G, Drake S K, Wood B J, Dreher M R. J. Control Release, 2010, 143: 265-273
[29] Moura V, Lacerda M, Figueiredo P, Corvo M L, Cruz M E, Soares R, de Lima M C, Simoes S, Moreira J N. Breast Cancer Res. Treat., 2012, 133: 61-73
[30] Ruoslahti E, Bhatia S N, Sailor M J. J. Cell. Biol., 2010, 188: 759-768
[31] Ran S, Volk L, Hall K, Flister M J. Pathophysiology, 2010, 17: 229-251
[32] Laakkonen P, Zhang L, Ruoslahti E. Ann. N. Y. Acad. Sci., 2008, 1131: 37-43
[33] Xin H, Sha X, Jiang X, Zhang W, Chen L, Fang X. Biomaterials, 2012, 33: 8167-8176
[34] Jain R K. Annu. Rev. Biomed. Eng., 1999, 1: 241-263
[35] Olive K P, Jacobetz M A, Davidson C J, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben M A, Caldwell M E, Allard D, Frese K K, Denicola G, Feig C, Combs C, Winter S P, Ireland-Zecchini H, Reichelt S, Howat W J, Chang A, Dhara M, Wang L, Ruckert F, Grutzmann R, Pilarsky C, Izeradjene K, Hingorani S R, Huang P, Davies S E, Plunkett W, Egorin M, Hruban R H, Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue C, Griffiths J, Tuveson D A. Science, 2009, 324: 1457-1461
[36] Primeau A J, Rendon A, Hedley D, Lilge L, Tannock I F. Clin. Cancer. Res., 2005, 11: 8782-8788
[37] Teesalu T, Sugahara K N, Kotamraju V R, Ruoslahti E. Proc. Natl. Acad. Sci. U. S. A., 2009, 106: 16157-16162
[38] Torchilin V. Eur. J. Pharm. Biopharm., 2009, 71: 431-444
[39] Sawant R M, Hurley J P, Salmaso S, Kale A, Tolcheva E, Levchenko T S, Torchilin V P. Bioconjug. Chem., 2006, 17: 943-949
[40] Li Y, Pan S, Zhang W, Du Z. Nanotechnology, 2009, 20: art. no. 065104
[41] Bae Y H. J. Control Release, 2009, 133: 2-3
[42] Lo A, Lin C T, Wu H C. Mol. Cancer Ther., 2008, 7: 579-589
[43] Gu F, Zhang L, Teply B A, Mann N, Wang A, Radovic-Moreno A F, Langer R, Farokhzad O C. Proc. Natl. Acad. Sci. U. S. A., 2008, 105: 2586-2591
[44] Ng C K, Pemberton H N, Reis-Filho J S. Expert. Rev. Anticancer. Ther., 2012, 12: 1021-1032
[45] Zhan C, Zhao L, Wei X, Wu X, Chen X, Yuan W, Lu W Y, Pazgier M, Lu W. J. Med. Chem., 2012, 55: 6237-6241
[46] Pujals S, Sabido E, Tarrago T, Giralt E. Biochem. Soc. Trans., 2007, 35: 794-796
[47] Pienta K J, McGregor N, Axelrod R, Axelrod D E. Transl. Oncol., 2008, 1: 158-164
[48] Kareva I. Transl. Oncol., 2011, 4: 266-270
[49] Pong W W, Gutmann D H. Oncogene, 2011, 30: 1135-1146
[50] Duan S, Yuan W, Wu F, Jin T. Angewandte Chemie, 2012, 51: 7938-7941
/
| 〈 |
|
〉 |
PDF
(1907KB)
